Eton Pharmaceuticals, Inc. (ETON) Current Ratio
- Current ratio · latest quarter: Value 1.52×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.52× | Current assets / current liabilities. $68.60M ÷ $45.12M ≈ 1.52× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 68.60M USD | Assets, Current |
| Current obligations | 45.12M USD | Liabilities, Current |
| Cash and equivalents | 26.84M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 24.89M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 10.14M USD | Inventory, Net |
| Payables | 14.40M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $68.60M | $45.12M | $26.84M | (m) | $24.89M | $10.14M | $14.40M | (m) | 1.52× |
| 2026-03-31 | $53.24M | $44.18M | $19.66M | (m) | $13.41M | $14.47M | $13.48M | (m) | 1.21× |
| 2025-12-31 | $60.58M | $38.49M | $25.94M | (m) | $11.76M | $15.42M | $10.98M | (m) | 1.57× |
| 2025-09-30 | $72.00M | $44.18M | $37.12M | (m) | $13.08M | $16.86M | $14.26M | (m) | 1.63× |
| 2025-06-30 | $68.44M | $38.60M | $25.38M | (m) | $14.45M | $23.79M | $12.14M | (m) | 1.77× |
| 2025-03-31 | $49.96M | $25.35M | $17.42M | (m) | $16.40M | $13.62M | $4.87M | (m) | 1.97× |
| 2024-12-31 | $41.02M | $19.95M | $14.94M | (m) | $5.36M | $15.23M | $4.17M | $0.00 | 2.06× |
| 2024-09-30 | $29.75M | $19.73M | $20.26M | (m) | $5.59M | $1.94M | $2.68M | $4.13M | 1.51× |
| 2024-06-30 | $25.43M | $18.22M | $17.69M | (m) | $4.87M | $2.07M | $2.13M | $4.66M | 1.40× |
| 2024-03-31 | $24.26M | $15.30M | $16.66M | (m) | $4.24M | $2.32M | $2.26M | $5.02M | 1.59× |
| 2023-12-31 | $26.84M | $16.24M | $21.39M | (m) | $3.41M | $911.00K | $1.85M | $5.38M | 1.65× |
| 2023-09-30 | $27.16M | $10.39M | $22.07M | (m) | $3.50M | $1.05M | $1.71M | $1.54M | 2.61× |
| 2023-06-30 | $26.33M | $9.59M | $21.57M | (m) | $3.08M | $816.00K | $2.30M | $1.54M | 2.75× |
| 2023-03-31 | $19.12M | $7.49M | $14.71M | (m) | $2.87M | $437.00K | $1.23M | $1.34M | 2.55× |
| 2022-12-31 | $20.00M | $6.46M | $16.30M | (m) | $1.85M | $557.00K | $1.77M | $1.03M | 3.10× |
| 2022-09-30 | $16.42M | $4.66M | $13.38M | (m) | $1.50M | $481.00K | $1.05M | $708.00K | 3.52× |
| 2022-06-30 | $19.78M | $3.81M | $17.05M | (m) | $834.00K | $531.00K | $1.30M | $364.00K | 5.19× |
| 2022-03-31 | $18.75M | $3.48M | $15.23M | (m) | $796.00K | $510.00K | $2.13M | (m) | 5.39× |
| 2021-12-31 | $23.60M | $4.56M | $14.41M | (m) | $5.47M | $550.00K | $1.77M | $1.42M | 5.18× |
| 2021-09-30 | $25.86M | $5.36M | $22.71M | (m) | $385.00K | $334.00K | $3.27M | $1.09M | 4.83× |
| 2021-06-30 | $29.07M | $3.11M | $25.80M | (m) | $303.00K | $1.24M | $1.52M | $749.00K | 9.36× |
| 2021-03-31 | $30.27M | $3.20M | $25.11M | (m) | $300.00K | $1.35M | $1.76M | $385.00K | 9.46× |
| 2020-12-31 | $24.70M | $3.79M | $21.30M | (m) | $48.00K | $1.24M | $2.34M | (m) | 6.51× |
| 2020-09-30 | $9.79M | $3.22M | $7.33M | (m) | (m) | $1.70M | $2.21M | (m) | 3.04× |
| 2020-06-30 | $12.82M | $2.74M | $10.27M | (m) | (m) | $1.71M | $1.95M | (m) | 4.68× |
| 2020-03-31 | $15.34M | $2.05M | $12.34M | (m) | $205.00K | $1.73M | $1.18M | (m) | 7.48× |
| 2019-12-31 | $15.01M | $1.96M | $12.07M | (m) | $473.00K | $380.00K | $575.00K | (m) | 7.65× |
| 2019-09-30 | $12.11M | $1.11M | $11.78M | (m) | (m) | (m) | $549.00K | (m) | 10.94× |
| 2019-06-30 | $16.75M | $1.46M | $14.95M | (m) | (m) | (m) | $883.00K | (m) | 11.48× |
| 2019-03-31 | $21.53M | $3.66M | $19.58M | (m) | (m) | (m) | $3.21M | (m) | 5.89× |
| 2018-12-31 | $27.50M | $2.02M | $26.73M | (m) | (m) | (m) | $1.42M | (m) | 13.59× |
| 2018-09-30 | $6.80M | $1.20M | $6.60M | (m) | (m) | (m) | $793.00K | (m) | 5.68× |
| 2017-12-31 | $13.29M | $793.00K | $13.16M | (m) | (m) | (m) | $539.00K | (m) | 16.76× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |